Old Web
English
Sign In
Acemap
>
authorDetail
>
Lucie Durand-Gasselin
Lucie Durand-Gasselin
Ipsen
Acromegaly
Lanreotide
Clinical trial
Medicine
Clinical endpoint
2
Papers
0
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Pharmacological and safety profile of a prolonged-release lanreotide formulation in acromegaly.
2021
Expert Review of Clinical Pharmacology
Sebastian J C M M Neggers
Corin Badiu
Betina Biagetti
Lucie Durand-Gasselin
Anne Petit
Patrick Petrossians
Benjamin Regnault
David Rich
Zulfiya Shafigullina
Sergey Shustov
Anna Vydrych
Show All
Source
Cite
Save
Citations (0)
Efficacy and safety of lanreotide autogel compared with lanreotide 40 mg prolonged release in Chinese patients with active acromegaly: results from a phase 3, prospective, randomized, and open-label study (LANTERN).
2020
BMC Endocrine Disorders
Zhen-Mei An
Ting Lei
Lian Duan
Pei Hu
ZhongPing Gou
Lihui Zhang
Lucie Durand-Gasselin
Nan Wang
Yan Wang
Feng Gu
Lantern study investigators
Show All
Source
Cite
Save
Citations (0)
1